Page 69 - GALENIKA MEDICAL JOURNAL

Literatura 13. Kim K, Lee SH. Effects of Statins for Primary Prevention in the
Elderly: Recent Evidence. J Lipid Atheroscler. 2020 Jan;9(1):1-7.
1. Davidovic MM. Therapeutic ageism. Eur J Intern Med. 2006 Jul;17(4):305. 14. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott
SD, et al; PROVE IT-TIMI 22 Investigators. Benefits of
2. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical achieving the NCEP optional LDL-C goal among elderly
pharmacology. Pharmacol Rev. 2004 Jun;56(2):163-84. patients with ACS. Eur Heart J. 2006 Oct;27(19):2310-6.
3. Reiter-Brennan C, Osei AD, Iftekhar Uddin SM, Orimoloye OA, Obisesan 15. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J,
OH, Mirbolouk M, et al. ACC/AHA lipid guidelines: Personalized care to Koylan N, et al. Effects of intensive versus moderate lipid-
prevent cardiovascular disease. Cleve Clin J Med. 2020 Apr;87(4):231-9. lowering therapy on myocardial ischemia in older patients with
coronary heart disease: results of the Study Assessing Goals in
4. KDIGO clinical practice guideline for lipid management in the Elderly (SAGE). Circulation. 2007 Feb 13;115(6):700-7.
chronic kidney disease. Kidney Int Suppl. 2013;3:263-4.
16. Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A,
5. Horodinschi RN, Stanescu AMA, Bratu OG, Pantea Stoian A, Goldstein LB, et al; SPARCL Investigators. Effect of atorvastatin
Radavoi DG, Diaconu CC. Treatment with Statins in Elderly in elderly patients with a recent stroke or transient
Patients. Medicina (Kaunas). 2019 Oct 30;55(11):721. ischemic attack. Neurology. 2009 Feb 24;72(8):688-94.
6. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; 17. Marshall B, Bennett N. PURL: How old is too old for
ASCOT Investigators. The Anglo-Scandinavian Cardiac statins? J Fam Pract. 2020 Jun;69(5):257-9.
Outcomes Trial: 11-year mortality follow-up of the lipid-lowering
arm in the U.K. Eur Heart J. 2011 Oct;32(20):2525-32. 18. Spencer-Bonilla G, Chung S, Heidenreich PA, Palaniappan LP,
Rodriguez F. Statin use for secundary prevention of cardiovascular
7. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker disease in the elderly. J Am Coll Cardiol. 2020;75(Suppl1):1891.
PM. Rosuvastatin for primary prevention in older persons
with elevated C-reactive protein and low to average low- 19. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd,
density lipoprotein cholesterol levels: exploratory analysis of a Goldstein LB, et al; American Heart Association Clinical Lipidology,
randomized trial. Ann Intern Med. 2010 Apr 20;152(8):488-96. Lipoprotein, Metabolism and Thrombosis Committee, a Joint
Committee of the Council on Atherosclerosis, Thrombosis and
8. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Vascular Biology and Council on Lifestyle and Cardiometabolic
et al; HOPE-3 Investigators. Cholesterol Lowering in Health; Council on Cardiovascular Disease in the Young; Council on
Intermediate-Risk Persons without Cardiovascular Disease. Clinical Cardiology; and Stroke Council. Statin Safety and Associated
N Engl J Med. 2016 May 26;374(21):2021-31. Adverse Events: A Scientific Statement From the American Heart
9. Ridker PM, Lonn E, Paynter NP, Glynn R, Yusuf S. Primary Association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81.
Prevention With Statin Therapy in the Elderly: New Meta- 20. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK,
Analyses From the Contemporary JUPITER and HOPE-3 Shear C; TNT Steering Committee Members and Investigators. Treating
Randomized Trials. Circulation. 2017 May 16;135(20):1979-81. to New Targets (TNT) Study: does lowering low-density lipoprotein
10. Cardiovascular disease: risk assessment and reduction, cholesterol levels below currently recommended guidelines yield
including lipid modification. [(accessed on 15 August 2019)]; incremental clinical benefit? Am J Cardiol. 2004 Jan 15;93(2):154-8.
Available online: https://www.nice.org.uk/guidance/cg181.
11. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et
al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ Konflikt interesa: Nema
PCNA Guideline on the Management of Blood Cholesterol: A Report of
the American College of Cardiology/American Heart Association Task Primljeno: 03. 02. 2022.
Force on Clinical Practice Guidelines. Circulation 2019139:1082-43. Prihvaćeno: 12. 04. 2022.
12. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon Onlajn: 30. 06. 2022.
L, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines
for the management of dyslipidaemias: lipid modification to
reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.

REVIJALNI RADOVI Galenika Medical Journal, 2022; 1(2):65-69. 69